Back to Journals » Drug Design, Development and Therapy » Beyond Brain Boundaries: Overcoming the Blood-Brain Barrier to Reach the Central Nervous System
Drug Design, Development and Therapy
ISSN: 1177-8881
- View all (4136)
- Volume 18, 2024 (97)
- Volume 17, 2023 (283)
- Volume 16, 2022 (316)
- Volume 15, 2021 (399)
- Volume 14, 2020 (477)
- Volume 13, 2019 (387)
- Volume 12, 2018 (382)
- Volume 11, 2017 (330)
- Volume 10, 2016 (374)
- Volume 9, 2015 (543)
- Volume 8, 2014 (231)
- Volume 7, 2013 (143)
- Volume 6, 2012 (42)
- Volume 5, 2011 (40)
- Volume 4, 2010 (35)
- Volume 3, 2009 (27)
- Volume 2, 2008 (29)
- Volume 1, 2007 (1)
Journal Articles:
- Beyond Brain Boundaries: Overcoming the Blood-Brain Barrier to Reach the Central Nervous System (1)
- Using Innovative Drug Delivery Systems to Improve the Efficacy and Applicability of Poorly Water-soluble Drugs (1)
- Advances in design and development of ophthalmic drugs (5)
- A cross-sectional survey on heart failure from China: disease burden and management (3)
- Ten Years of Biosimilars in Europe (4)
Beyond Brain Boundaries: Overcoming the Blood-Brain Barrier to Reach the Central Nervous System
The central nervous system (CNS) is the final frontier in drug delivery due to its intricate network of neurons and complex functions. Despite the increasing prevalence of CNS disorders worldwide, developing effective treatments remains challenging due to exorbitant costs, prolonged clinical pathways, and discouraging failure rates. The formidable barriers guarding the CNS, such as the blood-brain barrier and the blood-cerebrospinal fluid barrier, pose significant challenges, impeding the access of most drugs to their intended targets. This Article Collection delves into the realm of drug design and explores innovative strategies and breakthrough materials designed to surmount these barriers, facilitating precise and controlled drug delivery to the CNS. The collection aims to unravel the enigma of the CNS by paving the way for transformative therapies that can revolutionize the treatment of neurological and neuropsychiatric disorders.
Development and Characterization of a Novel Carbon-11 Labeled Positron Emission Tomography Radiotracer for Neuroimaging of Sirtuin 1 with Benzoxazine-Based Compounds
Wang Y, Liu Y, Wang Y, Bai P, Hallisey MR, Varela BL, Siewko A, Wang C, Xu Y
Drug Design, Development and Therapy 2024, 18:819-827
Published Date: 15 March 2024